Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab). acmcr. 2020;4(1):8-14. Accessed September 11, 2026. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22266